Toggle menu

Relax 2

Start date:
June 2014
End date:
January 2016 (Close to recruitment)
Co-ordinated by:
Main trial site:

A multicenter, randomised, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients (CRLXA).


To demonstrate that serelaxin is superior to placebo in reducing cardiovascular death in acute heart failure patients during a follow-up period of 180 days.

Trial Design

A randomised, double blind, placebo-controlled trial.

Chief Investigator

Metra Marco and Teerlink John for the RLX030A2301

Local PI

Dr Alasdair Gray

Research Team

Dr Martin Denvir – Co PI
Dr James Dear – Co PI
Dr Kristin Haga – Investigator
Dr Alastair Moss – Investigator
Polly Black – Research Nurse
Kirsty Simpson – Research Nurse
Rachel O’Brien – Research Nurse
Julia Grahamslaw – Research Nurse

Eligibility criteria (summary of )

Patients who are admitted to hospital with acute heart failure, who have received IV diuretics and have a degree of impaired renal function.

Local PI

Professor Alasdair Gray

Director of EMERGE & Consultant in Emergency Medicine

Research Team

Julia Grahamslaw

Lead Research Nurse

Kirsty Simpson

Senior Research Nurse

Rachel O'Brien

Lead Research Nurse

Polly Black

Senior Research Nurse

Emma Ward

Research Administrator

Related news

Research –A patient’s Perspective

Research –A patient’s Perspective

26 May 2015 | Polly Black

Meet Hilda. Hilda is 91 and has heart failure. In February 2015 participated in the RELAX 2 study and she kindly shared her experience with us.

Read more

More EMERGE Trials

Traumatic Brain Injury (TBI) is the leading cause of death and disabilities amongst young people worldwide. Many sufferers develop chronic physical and mental health problems and are unable to work or re-engage socially after their injuries. There are therefore significant health and socioeconomic consequences.

Read more


A study examining the Prevalence and Risk of Anterior Pituitary Dysfunction following Traumatic Brain Injury

1. Ambulatory Device, Rocket Pleural vent insertion
2. Standard Treatment, Aspiration +/- chest drain
Primary Outcome Measures
To assess whether use of an ambulatory device (Rocket Pleural Vent) and treatment strategy reduces hospital stay. Total length of stay in hospital up to 30 days post randomisation. Up to 30 days post randomisation.

Read more

RAMPP trial

RAMPP trial - Randomised Controlled Trial: Pleural vent (rocket) V standard care in Primary Spontaneous Pnuemothorax

Global Anticoagulant Registry in the FIELD observing treatment and outcomes in patients with treated acute Venous Thromboembolic Events in the real world

Read more


Global Anticoagulant Registry In the FIELD – Venous Thromboembolic Events